Cargando…

The Importance of Exosomal PD-L1 in Cancer Progression and Its Potential as a Therapeutic Target

Binding of programmed cell death ligand 1 (PD-L1) to its receptor programmed cell death protein 1 (PD-1) can lead to the inactivation of cytotoxic T lymphocytes, which is one of the mechanisms for immune escape of tumors. Immunotherapy based on this mechanism has been applied in clinic with some rem...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ye, Lingxiao, Zhu, Zhengxin, Chen, Xiaochuan, Zhang, Haoran, Huang, Jiaqi, Gu, Shengxian, Zhao, Xiaoyin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8619537/ https://www.ncbi.nlm.nih.gov/pubmed/34831468 http://dx.doi.org/10.3390/cells10113247

Ejemplares similares

The role of exosomal PD-L1 in tumor progression and immunotherapy
por: Xie, Feiting, et al.
Publicado: (2019)

Role of the Exosome in Ovarian Cancer Progression and Its Potential as a Therapeutic Target
por: Nakamura, Koji, et al.
Publicado: (2019)

Exosomal PD-L1: New Insights Into Tumor Immune Escape Mechanisms and Therapeutic Strategies
por: Zhou, Kaijian, et al.
Publicado: (2020)

Exosomal PD-L1 and N-cadherin predict pulmonary metastasis progression for osteosarcoma patients
por: Wang, Jun, et al.
Publicado: (2020)

The link between intracellular calcium signaling and exosomal PD-L1 in cancer progression and immunotherapy
por: Alam, Md Rakibul, et al.
Publicado: (2023)

Exosomal PD-L1: an effective liquid biopsy target to predict immunotherapy response
por: Song, Yanling, et al.
Publicado: (2019)

The role of exosomal PD-L1 in tumor immunotherapy
por: Wang, Jing, et al.
Publicado: (2021)

Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer
por: Niu, Mengke, et al.
Publicado: (2022)

Focus on PD-1/PD-L1 as a Therapeutic Target in Ovarian Cancer
por: Dumitru, Adrian, et al.
Publicado: (2022)

Exosomal PD-L1 Contributes to Immunosuppression and is Associated with anti-PD-1 Response
por: Chen, Gang, et al.
Publicado: (2018)

Tumor-Derived Exosomes: Hidden Players in PD-1/PD-L1 Resistance
por: Vautrot, Valentin, et al.
Publicado: (2021)

Clinical Implications of Exosomal PD-L1 in Cancer Immunotherapy
por: Ayala-Mar, Sergio, et al.
Publicado: (2021)

Jianpi Yangzheng Xiaozheng decoction alleviates gastric cancer progression via suppressing exosomal PD-L1
por: Chen, Yanzhen, et al.
Publicado: (2023)

PD-1 and PD-L1 as emerging therapeutic targets in gastric cancer: current evidence
por: Tran, Phu N, et al.
Publicado: (2017)

PPARα: A potential therapeutic target of cholestasis
por: Ye, Xiaoyin, et al.
Publicado: (2022)

Predictive and Prognostic Role of PD-L1 in Urothelial Carcinoma Patients with Anti-PD-1/PD-L1 Therapy: A Systematic Review and Meta-Analysis
por: Liu, Haoran, et al.
Publicado: (2020)

Exosomal circular RNAs: New player in breast cancer progression and therapeutic targets
por: Hussen, Bashdar Mahmud, et al.
Publicado: (2023)

Detection of Exosomal PD-L1 RNA in Saliva of Patients With Periodontitis
por: Yu, Jialiang, et al.
Publicado: (2019)

Exosomal PD-L1 functions as an immunosuppressant to promote wound healing
por: Su, Dandan, et al.
Publicado: (2019)

The Biogenesis, Biology, and Clinical Significance of Exosomal PD-L1 in Cancer
por: Tang, Yanyan, et al.
Publicado: (2020)

Heat Shock Proteins and PD-1/PD-L1 as Potential Therapeutic Targets in Myeloproliferative Neoplasms
por: De Almeida, Steven, et al.
Publicado: (2020)

Design strategies and application progress of therapeutic exosomes
por: Liu, Chunying, et al.
Publicado: (2019)

Anti-PD-1 Therapy Response Predicted by the Combination of Exosomal PD-L1 and CD28
por: Zhang, Chaoxu, et al.
Publicado: (2020)

Differences in treatment effect size between progression-free survival and overall survival in anti-PD-1/PD-L1 inhibitors-based trials in advanced NSCLC: a systematic review and meta-analysis
por: Zhou, Zhirui, et al.
Publicado: (2021)

Biodistribution of Exosomes and Engineering Strategies for Targeted Delivery of Therapeutic Exosomes
por: Choi, Hojun, et al.
Publicado: (2021)

The importance of the PD-1/PD-L1 pathway at the maternal-fetal interface
por: Meggyes, Matyas, et al.
Publicado: (2019)

Progress of research on PD-1/PD-L1 in leukemia
por: Cao, Huizhen, et al.
Publicado: (2023)

PD-1/PD-L1 Pathway: A Therapeutic Target in CD30+ Large Cell Lymphomas
por: Xie, Wei, et al.
Publicado: (2022)

PD1/PD-L1 immune checkpoint as a potential target for preventing brain tumor progression
por: Filippone, A., et al.
Publicado: (2022)

Targeting immune co-stimulatory effects of PD-L1 and PD-L2 might represent an effective therapeutic strategy in stroke
por: Bodhankar, Sheetal, et al.
Publicado: (2014)

CD73 and PD-L1 as Potential Therapeutic Targets in Gallbladder Cancer
por: Cao, Lu, et al.
Publicado: (2022)

Prognostic value of soluble PD-L1 and exosomal PD-L1 in advanced gastric cancer patients receiving systemic chemotherapy
por: Shin, Kabsoo, et al.
Publicado: (2023)

Tracking the evolution of circulating exosomal-PD-L1 to monitor melanoma patients
por: Cordonnier, Marine, et al.
Publicado: (2020)

Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1
por: Yin, Zi, et al.
Publicado: (2021)

The Role of Exosomes in the Progression and Therapeutic Resistance of Hematological Malignancies
por: Wang, Haobing, et al.
Publicado: (2022)

A nanounit strategy reverses immune suppression of exosomal PD-L1 and is associated with enhanced ferroptosis
por: Wang, Guohao, et al.
Publicado: (2021)

PD-1/PD-L1 Axis as a Potential Therapeutic Target for Multiple Sclerosis: A T Cell Perspective
por: Li, HaiXia, et al.
Publicado: (2021)

Revolutionization in Cancer Therapeutics via Targeting Major Immune Checkpoints PD-1, PD-L1 and CTLA-4
por: Pandey, Pratibha, et al.
Publicado: (2022)

Correction: Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1
Publicado: (2022)

Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling
por: De Sousa Linhares, Annika, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_n4map9s2curqu1iedclc7taaki